Static model simulation for routine mumps vaccination in Japan: with a result of mumps-related complications in a Japanese community hospital.
10.7774/cevr.2017.6.2.120
- Author:
Taito KITANO
1
;
Masayuki ONAKA
;
Mariko ISHIHARA
;
Atsuko NISHIYAMA
;
Naoki HASHIMOTO
;
Sayaka YOSHIDA
Author Information
1. Department of Pediatrics, Nara Prefecture General Medical Center, Nara City, Japan. taito.kitano0110@gmail.com
- Publication Type:Original Article
- Keywords:
Mumps vaccine;
Immunization program;
Cost-benefit analysis;
Quality adjusted life years
- MeSH:
Asian Continental Ancestry Group*;
Cost-Benefit Analysis;
Decision Trees;
Hospitals, Community*;
Humans;
Immunization Programs;
Japan*;
Mumps Vaccine;
Mumps*;
Quality-Adjusted Life Years;
Software Design;
Vaccination*
- From:Clinical and Experimental Vaccine Research
2017;6(2):120-127
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Mumps vaccine has not been included in the routine national immunization program in Japan, leading to low vaccine coverage rates and periodic epidemics approximately every 5 years. Our hospital (a secondary community hospital in Japan) experienced an increased number of mumps-related complications with a nationwide epidemic in 2016. Using previously reported data and mumps-related cases in our hospital, we estimated the cost-effectiveness of routine mumps vaccination in Japan with a static model using current epidemiologic data. MATERIALS AND METHODS: With a decision tree flowchart of mumps infection and adverse events, we estimated the burden of mumps-related complications in our hospital for 5 years, and calculated the current annual national burden. Finally, we compared the current burden and assumptive burden of the stable state after routine vaccination in Japan using a static model. RESULTS: The cost-benefit ratios with sensitivity analysis were 3.69 (1.08-9.52) and 6.84 (1.51-23.73) in independent inoculation and simultaneous inoculation, respectively, from a social perspective in addition to an annual gain of 9,487 (3,227-14,659) quality adjusted life years. CONCLUSION: We contributed additional evidence in terms of cost-effectiveness that routine mumps vaccination should be introduced in Japan with simultaneous inoculation.
